Abstract
Sepsis is a major cause of mortality during the neutropenic phase after intensive cytotoxic therapies for malignancies. Improved management of sepsis during neutropenia may reduce the mortality of cancer therapies. Clinical guidelines on sepsis treatment have been published by others. However, optimal management may differ between neutropenic and non-neutropenic patients. Our aim is to give evidence-based recommendations for haematologist, oncologists and intensive care physicians on how to manage adult patients with neutropenia and sepsis.
Highlights
Sepsis is a major cause of mortality during the neutropenic phase after intensive cytotoxic therapies for malignancies
The manuscript draft was peer reviewed by the review committee of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO) on October 1st, 2013
We suggest using the diagnostic consensus criteria for sepsis adapted to neutropenic patients (Table 2) [97, 98]
Summary
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Olaf Penack & Carolin Becker & Dieter Buchheidt & Maximilian Christopeit & Michael Kiehl & Marie von Lilienfeld-Toal & Marcus Hentrich & Marc Reinwald & Hans Salwender & Enrico Schalk & Martin Schmidt-Hieber & Thomas Weber & Helmut Ostermann. Received: 17 March 2014 / Accepted: 9 April 2014 / Published online: 29 April 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
